AI Tool Comparison
Comparing as AI Medical Imaging & DiagnosticsPathAI vs Viz.ai
Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.
PathAI
VS
Viz.ai
Verdict by Category
AI content generation failed. Refresh the page to try again.
Detailed Comparison
Feature
PathAI
Viz.ai
Pricing
EnterprisePathAI operates exclusively on enterprise contracts with hospitals, pathology labs, and biopharma companies — there is no published pricing or self-serve access. Following its acquisition by Roche in May 2026, PathAI's commercial and contract terms are managed through Roche's diagnostics division.
Clinical lab engagements use AISight for digital pathology workflow integration and AI algorithm deployment. Biopharma partnerships are structured as research service contracts for clinical trial tissue analysis, biomarker discovery, and companion diagnostic development.
Contact PathAI or Roche Diagnostics to explore enterprise and research partnership options.
CustomViz.ai operates exclusively on custom enterprise contracts with hospitals, health systems, and imaging networks. There is no published pricing or self-serve access.
Pricing is negotiated based on hospital type, imaging volume, number of conditions covered, and multi-site deployment needs. Viz.ai's Medicare NTAP designation provides hospitals with an additional reimbursement of approximately $1,040 per qualifying patient encounter, partially offsetting platform costs.
Contact Viz.ai through viz.ai to schedule a demo and begin enterprise procurement discussions.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
AI-powered digital pathology platform for oncology diagnostics and biopharma R&D — now part of Roche
AI care coordination platform for stroke, PE, and aortic disease — FDA-cleared algorithms alerting care teams in minutes
PathAI Pros & Cons
Pros
- Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
- 32.5M+ expert annotations — one of the world's largest pathology AI training datasets
- 20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
- AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
- CLIA-certified lab services for biopharma clinical trial support
- Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
- First AI pathology company recognized as a leader in CB Insights Digital Pathology market map
Cons
- Acquired by Roche in May 2026 — future product roadmap and independent operations may change
- Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
- No self-serve pricing or trial — all engagements are through enterprise procurement
- Requires digital pathology infrastructure (scanners, storage, LIS integration)
- Integration complexity for labs not yet on digital pathology workflows
Viz.ai Pros & Cons
Pros
- 12 FDA-cleared algorithms — broadest acute-condition AI portfolio in its class
- Medicare NTAP reimbursement pathway — unique among AI imaging platforms
- 44% reduction in DIDO times for stroke patients — peer-reviewed clinical evidence (ISC 2026)
- 1,000+ hospital deployments across U.S. and Europe
- Backed by Google Ventures, Kleiner Perkins, and Tiger Global — $289M raised
- Simultaneous mobile alerts to full care team — no phone-tag delays
- Expands from neurology to cardiology and pulmonology in one unified platform
Cons
- Enterprise-only pricing — no self-serve or small clinic access
- No published pricing — all contracts are custom
- Primarily focused on acute/time-sensitive conditions — not general radiology reads
- Requires integration with existing hospital imaging infrastructure
- Implementation and onboarding take time for large multi-site systems